Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 29th 2021

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

R/R Follicular Lymphoma: Testing for EZH2

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 29th 2021

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Evolving Therapies in R/R DLBCL: Concluding Remarks

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 22nd 2021

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 22nd 2021

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

$Treating Primary Refractory DLBCL$

Treating Primary Refractory DLBCL

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

Bridging Therapy in R/R DLBCL

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

R2 Regimen for R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 15th 2021

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

PI3K Inhibitors for R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 15th 2021

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

R/R DLBCL: Transplants in the Era of CAR-T

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

R/R Follicular Lymphoma: Third-Line Treatment Options

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 8th 2021

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

Transplantation for R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 8th 2021

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

CAR T for R/R DLBCL: Safety/Tolerability

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

MRD Testing in R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 1st 2021

Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.

Role of Rebiopsy in R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute

March 1st 2021

The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.